Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Journal Title
Onco Targets and Therapy
Publication Type
Journal Article
Abstract
Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways. Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are aberrantly activated in most common tumors, including leukemia, glioblastoma, gastrointestinal stromal tumors, non-small-cell lung cancer, and head and neck cancers. Iclusig (ponatinib, previously known as AP24534) is an orally active multi-tyrosine kinase inhibitor and is currently approved by the US Food and Drug Administration for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, specifically targeting the BCR-ABL gene mutation, T315I. Due to ponatinib's unique multi-targeted characteristics, further studies have demonstrated its ability to target other important tyrosine kinases (FGFR, PDGFR, SRC, RET, KIT, and FLT1) in other human malignancies. This review focuses on the available data of ponatinib and its molecular targets for treatment in various cancers, with a discussion on the broader potential of this agent in other cancer indications.
Publisher
Dove Medical Press
WEHI Research Division(s)
Personalised Oncology
PubMed ID
30705592
Open Access at Publisher's Site
https://doi.org/10.2147/OTT.S189391
NHMRC Grants
NHMRC/1080498
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2019-03-13 08:04:19
Last Modified: 2019-03-13 09:55:02
An error has occurred. This application may no longer respond until reloaded. Reload 🗙